Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of GLPG3970, Administered Orally for 6 Weeks in Adult Subjects With Moderately to Severely Active Ulcerative Colitis
Conditions
Interventions
GLPG3970
Placebo
Locations
15
Georgia
Arensia Exploratory Medicine LLC
Tbilisi, Georgia
ARENSIA Exploratory Medicine Phase I Unit
Chisinau, Moldova
Centrum Medyczne PROMED
Krakow, Poland
Endoskopia Sp. z o.o.
Sopot, Poland
ETG Zamosc
Zamość, Poland
I.I.Mechnykov Dnipropetrovsk Regional Clinical Hospital
Dnipro, Ukraine
Start Date
October 5, 2020
Primary Completion Date
May 17, 2021
Completion Date
May 31, 2021
Last Updated
January 27, 2023
NCT07271069
NCT06975722
NCT07185009
NCT07184996
NCT07245394
NCT07089420
Lead Sponsor
Galapagos NV
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions